New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance
H7N9 influenza viruses are predominately avian (bird) pathogens, however, since 2013, they have infected more than 1500 humans with a mortality rate of nearly 40% in confirmed cases. H7N9 viruses continue to be a threat to public health. Treatment for people infected with H7N9-subtype influenza A (H7N9) commonly includes the use of drugs that inhibit neuraminidase, a protein found on the virus’ surface. However, like other influenza viruses, H7N9 can become resistant to these drugs.
CDC researchers have developed a monoclonal antibody (mAb) that binds to the neuraminidase protein of H7N9 influenza viruses, and has been shown in animal studies to provide protection from H7N9 infection. Because this antibody targets a different region of the neuraminidase protein than other antibodies, it is unlikely that H7N9 strains have developed resistance to it, making it an ideal starting point for antibody-based therapy or prevention of H7N9 infection. This technology could be used alone, or in combination with other neuraminidase inhibitor drugs. The antibody can also be useful as a research material. It will need to be humanized in further research.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Inventors:
Jason Wilson (CDC) ➽ more inventions...
Ian York (CDC) ➽ more inventions...
James Stevens (CDC) ➽ more inventions...
Zhu Guo (CDC) ➽ more inventions...
Intellectual Property:
US Application No. 62/365,264
Patent protection is not being pursued for this technology.
Publications:
Wilson JR., et al. PMID 28888111
Wilson JR., et al. PMID 27713074
Collaboration Opportunity:
The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance. For collaboration opportunities, please contact CDC TTO at tto@cdc.govor 1-404-639-1330.
Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719
OTT Reference No: E-200-2016-0
Updated: Jun 20, 2018